Publications
Detailed Information
Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, H. S. | - |
dc.contributor.author | Han, K. H. | - |
dc.contributor.author | Chung, H. H. | - |
dc.contributor.author | Kim, J. W. | - |
dc.contributor.author | Song, Y. S. | - |
dc.contributor.author | Kang, S. B. | - |
dc.contributor.author | Park, N. H. | - |
dc.date.accessioned | 2012-06-05T01:19:43Z | - |
dc.date.available | 2012-06-05T01:19:43Z | - |
dc.date.issued | 2010-07 | - |
dc.identifier.citation | EJSO; Vol.36 7; 691-698 | ko_KR |
dc.identifier.issn | 0748-7983 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76827 | - |
dc.description.abstract | Background: Uterine sarcomas are rare among all uterine malignancies, and frequently misdiagnosed as benign uterine diseases such as leiomyoma and adenomyosis because of lack of feasible tools for the preoperative diagnosis. Although some studies have suggested the role of serum CA-125 levels for the preoperative diagnosis, the efficacy is controversial. Since malignancy is known to be associated with systemic inflammation which leads to hematological alteration, we compared the efficacy for the preoperative diagnosis of uterine sarcomas between the neutrophil to lymphocyte ratio (NLR) and serum CA-125 levels using a case-match comparison. Methods: From November 2004 to December 2008, 55 patients with carcinosarcoma (n = 21), leiomyosarcoma (n = 20) and endometrial stromal sarcoma (n = 14) were matched to 330 patients with leiomyoma (n = 165) and adenomyosis (n = 165) in terms of age at diagnosis, body mass index and uterine volume. Results: The receiver operating characteristic curve showed the best cut-off values of the NLR (>= 2.12) and serum CA-125 levels (>= 27.5 U/ml) for the preoperative diagnosis of uterine sarcomas, demonstrating that the NLR was more powerful for the preoperative diagnosis of uterine sarcomas than serum CA-125 levels (sensitivity, 74.5% vs. 52.3%; specificity, 70.3% vs. 50.5%; positive predictive value, 29.5% vs. 15.1%; negative predictive value, 94.3% vs. 86.5%; accuracy, 60.6% vs. 49.6%; p<0.05). Furthermore, the NLR reflected recurrence and progression more accurately than serum CA-125 levels in patients with uterine sarcomas. Conclusions: These findings suggest that the NLR may be more useful than serum CA-125 levels as a cost-effective tool for the preoperative diagnosis in patients with uterine sarcomas. (C) 2010 Elsevier Ltd. All rights reserved. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCI LTD | ko_KR |
dc.subject | Neutrophil to lymphocyte ratio | ko_KR |
dc.subject | Leiomyoma | ko_KR |
dc.subject | Adenomyosis | ko_KR |
dc.subject | Uterine sarcomas | ko_KR |
dc.subject | Serum CA-125 levels | ko_KR |
dc.title | Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: A case-matched comparison | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1016/j.ejso.2010.05.004 | - |
dc.citation.journaltitle | EJSO | - |
dc.description.citedreference | D`Angelo E, 2010, GYNECOL ONCOL, V116, P131, DOI 10.1016/j.ygyno.2009.09.023 | - |
dc.description.citedreference | Ray-Coquard I, 2009, CANCER RES, V69, P5383, DOI 10.1158/0008-5472.CAN-08-3845 | - |
dc.description.citedreference | McMillan DC, 2009, CURR OPIN CLIN NUTR, V12, P223, DOI 10.1097/MCO.0b013e32832a7902 | - |
dc.description.citedreference | Cho H, 2009, CANCER IMMUNOL IMMUN, V58, P15, DOI 10.1007/s00262-008-0516-3 | - |
dc.description.citedreference | Shan WW, 2009, FRONT BIOSCI, V14, P4044, DOI 10.2741/3511 | - |
dc.description.citedreference | Hoskins PJ, 2008, INT J GYNECOL CANCER, V18, P1200, DOI 10.1111/j.1525-1438.2007.01187.x | - |
dc.description.citedreference | Park JY, 2008, GYNECOL ONCOL, V109, P255, DOI 10.1016/j.ygyno.2008.01.030 | - |
dc.description.citedreference | Huang GS, 2007, GYNECOL ONCOL, V107, P513, DOI 10.1016/j.ygyno.2007.08.060 | - |
dc.description.citedreference | RYU HS, 2007, J GYNECOL ONCOL, V50, P1299 | - |
dc.description.citedreference | Herishanu Y, 2006, EUR J HAEMATOL, V76, P516, DOI 10.1111/j.1600-0609.2006.00658.x | - |
dc.description.citedreference | OLIVARES M, 2006, REV MED CHILE, V122, P1289 | - |
dc.description.citedreference | Walsh Sr, 2005, J SURG ONCOL, V91, P181, DOI 10.1002/jso.20329 | - |
dc.description.citedreference | Tanaka YO, 2004, J MAGN RESON IMAGING, V20, P998, DOI 10.1002/jmri.20207 | - |
dc.description.citedreference | Lin EY, 2004, BRIT J CANCER, V90, P2053, DOI 10.1038/sj.bjc.6601705 | - |
dc.description.citedreference | Barba C, 2004, LANCET, V363, P157 | - |
dc.description.citedreference | BLAKEMORTIMER JS, 2004, BREAST J, V10, P195 | - |
dc.description.citedreference | BROOKS SE, 2004, GYNECOL ONCOL, V93, P204 | - |
dc.description.citedreference | Sagae S, 2004, ONCOLOGY-BASEL, V67, P33, DOI 10.1159/000080283 | - |
dc.description.citedreference | TAVASSOLI FA, 2003, PATHOLOGY GENETICS T | - |
dc.description.citedreference | Wang X, 2002, ACTA CYTOL, V46, P465 | - |
dc.description.citedreference | Kawamura N, 2002, CANCER, V94, P1713, DOI 10.1002/cncr.10382 | - |
dc.description.citedreference | Tsujimura A, 2002, INT J ONCOL, V20, P361 | - |
dc.description.citedreference | Ruka W, 2001, ANN ONCOL, V12, P1423 | - |
dc.description.citedreference | Jilma B, 1999, AM J RESP CRIT CARE, V159, P857 | - |
dc.description.citedreference | denOuden M, 1997, EUR J OBSTET GYN R B, V72, P73 | - |
dc.description.citedreference | NORDAL RR, 1995, ACTA ONCOL, V34, P797 | - |
dc.description.citedreference | DUK JM, 1994, INT J GYNECOL CANCER, V4, P156 | - |
dc.description.citedreference | WOLFSON AH, 1994, GYNECOL ONCOL, V52, P56 | - |
dc.description.citedreference | PATSNER B, 1988, CANCER, V62, P1355 | - |
dc.description.citedreference | ANTHONY HM, 1982, BRIT J CANCER, V45, P209 | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.